GLP-1 News — Week of June 1, 2026
The GLP-1 stories that mattered this week — each one summarised neutrally and linked to its primary source. Nothing here is influenced by advertisers.
FDA issues new safety alert on dosing errors with compounded injectable semaglutide
The FDA warned health care providers, compounders, and patients about serious dosing errors linked to compounded injectable semaglutide, often dispensed in multi-dose vials and measured in syringe units instead of fixed-dose pens. Reports include patients receiving significantly higher doses than intended, leading to severe gastrointestinal symptoms, dehydration, and other adverse events, and the agency urges careful review of dosing instructions and consideration of approved products when feasible. (2026-06-02)
Source: FDA
Related on Metabolic Ledger: /drugs/compounded-to-brand-dose-conversion
Consumer update details Medicare GLP-1 Bridge program offering $50 monthly copays
The Medicare Rights Center outlined CMS’s upcoming Medicare GLP-1 Bridge demonstration, which will allow eligible beneficiaries to access certain GLP-1 weight-loss medications for a flat $50 monthly copay from July 1 through December 31, 2026. The piece explains that this temporary bridge will be followed by the broader BALANCE model in 2027 and encourages patients and caregivers to review eligibility criteria and plan communications ahead of the rollout. (2026-06-04)
Source: Medicare Rights Center
Related on Metabolic Ledger: /cost/medicare-glp1-coverage
WeightWatchers Med+ program integrates with LillyDirect for GLP-1 access
WW International announced that its Med+ program, which combines virtual medical care, behavior change support, and GLP-1 prescribing, is now accessible through Lilly’s LillyDirect telehealth and pharmacy platform. This linkage may simplify access to drugs like Zepbound and Mounjaro by giving patients a single digital pathway for evaluation, prescribing, and medication fulfillment, particularly in regions with limited in-person obesity medicine services. (2026-06-04)
Source: WeightWatchers
Related on Metabolic Ledger: /providers/weightwatchers-clinic-review
Week-one launch data show rapid uptake for Lilly’s oral GLP-1 Foundayo versus Wegovy pill
Fierce Pharma’s oral GLP-1 tracker reports that Lilly’s new oral GLP-1, Foundayo, posted strong first-week prescription numbers, outpacing the initial trajectory seen with Novo Nordisk’s Wegovy pill launch. The early data suggest growing demand for oral GLP-1 options among people with type 2 diabetes and obesity, though long-term access will depend on pricing, insurance coverage, and how clinicians position these pills relative to injectable therapies. (2026-06-01)
Source: Fierce Pharma
Related on Metabolic Ledger: /drugs/orforglipron
Lilly expands Camurus collaboration to long-acting GLP-1, GIP, glucagon, and amylin drugs for obesity
Camurus announced that Eli Lilly has expanded their collaboration to cover up to four Lilly pipeline compounds, including dual GLP-1/GIP and triple GLP-1/GIP/glucagon receptor agonists as well as amylin receptor agonists, potentially formulated with Camurus’s long-acting depot technology. The deal, which includes up to SEK 10.1 billion in milestones plus royalties for Camurus, aims to develop less frequent injectable treatments for obesity and metabolic disease that could be dosed monthly or longer-term. (2026-06-01)
Source: Camurus
Related on Metabolic Ledger: /drugs/cagrisema